Vaxcyte (NASDAQ:PCVX) EVP Jim Wassil Sells 1,334 Shares of Stock

Vaxcyte, Inc. (NASDAQ:PCVX) EVP Jim Wassil sold 1,334 shares of the stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $59.52, for a total transaction of $79,399.68. Following the transaction, the executive vice president directly owned 145,435 shares in the company, valued at $8,656,291.20. The trade was a 0.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Jim Wassil also recently made the following trade(s):

• On Friday, September 4th, Jim Wassil sold 1,381 shares of Vaxcyte stock. The stock was sold at an average price of $61.16, for a total value of $84,461.96.
• On Tuesday, September 1st, Jim Wassil sold 3,477 shares of Vaxcyte stock. The shares were sold at an average price of $61.07, for a total value of $212,340.39.
• On Monday, August 3rd, Jim Wassil sold 2,250 shares of Vaxcyte stock. The shares were sold at an average price of $53.86, for a total value of $121,185.00.
• On Wednesday, July 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $56.33, for a total value of $126,742.50.

Vaxcyte Trading Down 1.4%

Shares of PCVX opened at $59.51 on Thursday. The firm has a market cap of $8.86 billion, a price-to-earnings ratio of -7.80 and a beta of 1.22. The stock has a 50 day moving average of $58.41 and a 200-day moving average of $56.32. Vaxcyte, Inc. has a 52 week low of $30.81 and a 52 week high of $65.00.

Vaxcyte (NASDAQ:PCVX) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($1.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.06) by $0.09. During the same period last year, the business earned ($1.22) EPS. On average, sell-side analysts predict that Vaxcyte, Inc. will post -7.6 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Smartleaf Asset Management LLC grew its stake in Vaxcyte by 156.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 597 shares of the company’s stock worth $27,000 after buying an additional 364 shares during the last quarter. Caitong International Asset Management Co. Ltd lifted its stake in Vaxcyte by 1,463.4% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 641 shares of the company’s stock valued at $30,000 after buying an additional 600 shares during the last quarter. IFP Advisors Inc lifted its stake in Vaxcyte by 72.8% in the second quarter. IFP Advisors Inc now owns 560 shares of the company’s stock valued at $33,000 after buying an additional 236 shares during the last quarter. EverSource Wealth Advisors LLC boosted its holdings in shares of Vaxcyte by 33.0% during the fourth quarter. EverSource Wealth Advisors LLC now owns 741 shares of the company’s stock valued at $34,000 after acquiring an additional 184 shares during the period. Finally, CIBC Private Wealth Group LLC boosted its holdings in shares of Vaxcyte by 22,500.0% during the third quarter. CIBC Private Wealth Group LLC now owns 1,356 shares of the company’s stock valued at $49,000 after acquiring an additional 1,350 shares during the period. Institutional investors and hedge funds own 96.78% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on PCVX. Zacks Research raised shares of Vaxcyte from a “strong sell” rating to a “hold” rating in a report on Wednesday, August 12th. Wall Street Zen raised shares of Vaxcyte from a “strong sell” rating to a “sell” rating in a report on Saturday, August 8th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Five investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Vaxcyte has a consensus rating of “Moderate Buy” and a consensus price target of $86.00.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.